# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

> **NCT02212925** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 38 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** BI 14332 CL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02212925
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2007-03
- **Final completion:** —
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02212925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02212925, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02212925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*